We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Visby Medical

Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, ta... read more Featured Products: More products

Download Mobile App




POC STI Test Shortens Time from ED Arrival to Test Results

By LabMedica International staff writers
Posted on 04 Jun 2024

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2. More...

5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics to treat these STIs. This misuse has contributed to the development of antimicrobial-resistant strains of Neisseria gonorrhoeae (NG), prompting WHO to issue new guidelines for diagnosing STIs, including the use of point-of-care (POC) tests, focusing particularly on reducing antimicrobial resistance. The increasing STI rates have posed a significant challenge to hospital emergency departments, as traditional tests do not yield results quickly enough to guide treatment decisions during a patient's visit. Consequently, clinicians often must decide on treatment before obtaining definitive results, exacerbating the issue of antibiotic resistance.

Now, a new study has demonstrated that a POC polymerase chain reaction (PCR) test can reduce the time from specimen collection to STI result to just 47 minutes per patient, compared to the 25-hour average with the standard of care (SOC) lab-processed molecular send-out tests. This test also led to significantly higher rates of appropriate treatment and lower rates of antibiotic over-treatment for Chlamydia trachomatis (CT) and NG infections, relative to SOC. Conducted by Visby Medical (San Jose, CA, USA) and John Hopkins University (Baltimore, MD, USA), the study assessed a new approach to managing the three most common non-viral STIs in women, comparing two testing methods at the Johns Hopkins Emergency Department over two separate four-month study periods in 2022 and 2023.

The two methods included SOC central laboratory testing with batched nucleic acid amplification testing (NAAT) and the POC PCR Visby Medical Sexual Health Test. They were evaluated for STI detection rates, median time-to-result intervals, and rates of appropriate treatment according to CDC guidelines. The Visby Medical Sexual Health Test, an "instrument-free" POC test that delivers PCR results in under 30 minutes, is the only one of its kind available in the U.S. In March 2023, this test received 510(k) clearance and a CLIA waiver from the U.S. Food and Drug Administration for its second-generation POC test. The study found that appropriate treatment proportions were significantly higher in the POC group. Additionally, the median time intervals for the POC group were significantly shorter, including the time from specimen collection to STI results, the time from patient arrival in the emergency department to STI results, and the time from ED arrival to patient discharge.

“The dramatic improvements seen with the Visby Sexual Health test in testing time, ED visit duration, and in the use of antibiotics point the way toward a new best practice for STI testing,” said Gary Schoolnik, MD, an infectious disease expert, Chief Medical Officer at Visby Medical, and Professor of Medicine at Stanford University. “Implementation of a new rapid point-of-care testing standard of care would greatly benefit our hospitals, urgent care centers and, most importantly, women who seek treatment for this condition.”

Related Links:
Visby Medical
John Hopkins University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Automatic CLIA Analyzer
Shine i6000
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.